GHK-Cu and Rosuvastatin Interaction: Safety, Mechanisms, and Clinical Guidance At a glance Direct interaction evidence / none published as of May 2026 GHK-Cu metabolism / peptidase degradation, not CYP-mediated Rosuvastatin metabolism / minimal CYP2C9, primarily OATP1B1/1B3 hepatic uptake Overlapping CYP liability / none identified Copper load concern / low at typical GHK-Cu doses (1-3 mg/day subcutaneous) Rosuvastatin muscle risk / myopathy incidence approximately 0.1% per FDA label Monitoring recommendation / CK at baseline and if symptoms arise
Our team ensures you understand needle replacement, site rotation, and storage requirements specific to your compounded formulation
Following single administration, the elimination half-life of prototype BPC-157 was less than 30 minutes in both species, indicating rapid systemic clearance
Elko Replenish Med Spa proudly provides PT-141 peptide therapy and personalized wellness services to patients throughout Elko, Spring Creek, Carlin, Lamoille, Wells, Battle Mountain, Wendover, Jackpot, and other surrounding communities across northeastern Nevada
Loss of Strength and Coordination Research shows muscle quality may decline with GLP-1 use, not just size